<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd"><article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article" xml:lang="EN"><front><journal-meta><journal-id journal-id-type="nlm-ta">PLoS ONE</journal-id><journal-id journal-id-type="publisher-id">plos</journal-id><journal-id journal-id-type="pmc">plosone</journal-id><journal-title>PLoS ONE</journal-title><issn pub-type="epub">1932-6203</issn><publisher><publisher-name>Public Library of Science</publisher-name><publisher-loc>San Francisco, USA</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">08-PONE-RA-05783R1</article-id><article-id pub-id-type="doi">10.1371/journal.pone.0004270</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="Discipline"><subject>Respiratory Medicine</subject><subject>Genetics and Genomics/Complex Traits</subject><subject>Genetics and Genomics/Genetics of Disease</subject><subject>Genetics and Genomics/Genetics of the Immune System</subject><subject>Genetics and Genomics/Medical Genetics</subject><subject>Genetics and Genomics/Microbial Evolution and Genomics</subject><subject>Infectious Diseases/Bacterial Infections</subject><subject>Infectious Diseases/Respiratory Infections</subject><subject>Respiratory Medicine/Respiratory Infections</subject><subject>Respiratory Medicine/Respiratory Pediatrics</subject></subj-group></article-categories><title-group><article-title>Histo-Blood Group Gene Polymorphisms as Potential Genetic Modifiers of Infection and Cystic Fibrosis Lung Disease Severity</article-title><alt-title alt-title-type="running-head">ABH Gene Polymorphisms in CF</alt-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Taylor-Cousar</surname><given-names>Jennifer L.</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="corresp" rid="cor1"><sup>&#x0002a;</sup></xref></contrib><contrib contrib-type="author"><name><surname>Zariwala</surname><given-names>Maimoona A.</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Burch</surname><given-names>Lauranell H.</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref></contrib><contrib contrib-type="author"><name><surname>Pace</surname><given-names>Rhonda G.</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Drumm</surname><given-names>Mitchell L.</given-names></name><xref ref-type="aff" rid="aff6"><sup>6</sup></xref></contrib><contrib contrib-type="author"><name><surname>Calloway</surname><given-names>Hollin</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Fan</surname><given-names>Haiying</given-names></name><xref ref-type="aff" rid="aff5"><sup>5</sup></xref></contrib><contrib contrib-type="author"><name><surname>Weston</surname><given-names>Brent W.</given-names></name><xref ref-type="aff" rid="aff5"><sup>5</sup></xref></contrib><contrib contrib-type="author"><name><surname>Wright</surname><given-names>Fred A.</given-names></name><xref ref-type="aff" rid="aff4"><sup>4</sup></xref></contrib><contrib contrib-type="author"><name><surname>Knowles</surname><given-names>Michael R.</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author"><collab>for the Gene Modifier Study Group</collab></contrib></contrib-group><aff id="aff1"><label>1</label><addr-line>University of New Mexico Health Sciences Center, Pulmonary Divisions, Internal Medicine and Pediatrics, Albuquerque, New Mexico, United States of America</addr-line></aff><aff id="aff2"><label>2</label><addr-line>University of North Carolina, Cystic Fibrosis/Pulmonary Research and Treatment Center, Chapel Hill, North Carolina, United States of America</addr-line></aff><aff id="aff3"><label>3</label><addr-line>National Institute of Environmental Health Sciences, Research Triangle Park, North Carolina, United States of America</addr-line></aff><aff id="aff4"><label>4</label><addr-line>University of North Carolina, Department of Biostatistics, Chapel Hill, North Carolina, United States of America</addr-line></aff><aff id="aff5"><label>5</label><addr-line>University of North Carolina, Hematology-Oncology, Department of Pediatrics, Chapel Hill, North Carolina, United States of America</addr-line></aff><aff id="aff6"><label>6</label><addr-line>Case Western Reserve University, Pediatric Pulmonary Division, Department of Pediatrics, Cleveland, Ohio, United States of America</addr-line></aff><contrib-group><contrib contrib-type="editor"><name><surname>Toland</surname><given-names>Amanda Ewart</given-names></name><role>Editor</role><xref ref-type="aff" rid="edit1"/></contrib></contrib-group><aff id="edit1">Ohio State University Medical Center, United States of America</aff><author-notes><corresp id="cor1">&#x0002a; E-mail: <email>JTCousar@salud.unm.edu</email></corresp><fn fn-type="con"><p>Conceived and designed the experiments: JLTC MAZ LHB RGP MLD HF BWW MRK. Performed the experiments: JLTC RGP. Analyzed the data: JLTC LHB MLD HC HF FW MRK. Contributed reagents/materials/analysis tools: MAZ LHB BWW. Wrote the paper: JLTC MRK.</p></fn></author-notes><pub-date pub-type="collection"><year>2009</year></pub-date><pub-date pub-type="epub"><day>26</day><month>1</month><year>2009</year></pub-date><volume>4</volume><issue>1</issue><elocation-id>e4270</elocation-id><history><date date-type="received"><day>1</day><month>8</month><year>2008</year></date><date date-type="accepted"><day>24</day><month>11</month><year>2008</year></date></history><copyright-statement>Taylor-Cousar et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</copyright-statement><copyright-year>2009</copyright-year><abstract><sec><title>Background</title><p>The pulmonary phenotype in cystic fibrosis (CF) is variable; thus, environmental and genetic factors likely contribute to clinical heterogeneity. We hypothesized that genetically determined ABO histo-blood group antigen (ABH) differences in glycosylation may lead to differences in microbial binding by airway mucus, and thus predispose to early lung infection and more severe lung disease in a subset of patients with CF.</p></sec><sec><title>Methods and Principal Findings</title><p>Clinical information and DNA was collected on &#x0003e;800 patients with the &#x00394;F508/&#x00394;F508 genotype. Patients in the most severe and mildest quartiles for lung phenotype were enrolled. Blood samples underwent lymphocyte transformation and DNA extraction using standard methods. PCR and sequencing were performed using standard techniques to identify the 9 SNPs required to determine ABO blood type, and to identify the four SNPs that account for 90&#x02013;95&#x00025; of Lewis status in Caucasians. Allele identification of the one nonsynonymous SNP in FUT2 that accounts for &#x0003e;95&#x00025; of the incidence of nonsecretor phenotype in Caucasians was completed using an ABI Taqman assay. The overall prevalence of ABO types, and of FUT2 (secretor) and FUT 3 (Lewis) alleles was consistent with that found in the Caucasian population. There was no difference in distribution of ABH type in the severe versus mild patients, or the age of onset of <italic>Pseudomonas aeruginosa</italic> infection in the severe or mild groups. Multivariate analyses of other clinical phenotypes, including gender, asthma, and meconium ileus demonstrated no differences between groups based on ABH type.</p></sec><sec><title>Conclusions and Significance</title><p>Polymorphisms in the genes encoding ABO blood type, secretor or Lewis genotypes were not shown to associate with severity of CF lung disease, or age of onset of <italic>P. aeruginosa</italic> infection, nor was there any association with other clinical phenotypes in a group of 808 patients homozygous for the &#x00394;F508 mutation.</p></sec></abstract><counts><page-count count="7"/></counts></article-meta></front><body><sec id="s1"><title>Introduction</title><p>Cystic fibrosis (CF) is the most common life shortening genetic disorder in Caucasians, and occurs in 1 in 3200 Caucasians in the U.S. <xref ref-type="bibr" rid="pone.0004270-Bobadilla1">&#x0005b;1&#x0005d;</xref> Since the identification of the CF gene in 1989 <xref ref-type="bibr" rid="pone.0004270-Riordan1">&#x0005b;2&#x0005d;</xref>, over 1500 mutations in the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) have been associated with CF. <xref ref-type="bibr" rid="pone.0004270-Cystic1">&#x0005b;3&#x0005d;</xref> The most common mutation, &#x00394;F508, occurs in &#x0223c;70&#x00025; of CFTR alleles. <xref ref-type="bibr" rid="pone.0004270-Bobadilla1">&#x0005b;1&#x0005d;</xref> Although numerous mutations in the CF gene have been described, there is little correlation between the specific mutation in the CF gene and severity of pulmonary disease. Recent investigations have focused on the identification of other non-CF gene variants that may affect the phenotype, i.e. &#x0201c;modifier genes.&#x0201d; <xref ref-type="bibr" rid="pone.0004270-Cutting1">&#x0005b;4&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0004270-Boyle1">&#x0005b;5&#x0005d;</xref></p><p>Mutations in CFTR cause CF, and the initial pathophysiology of the lung disease involves defective ion transport, dehydration of the mucous layer, and reduced mucociliary and cough clearance. <xref ref-type="bibr" rid="pone.0004270-Knowles1">&#x0005b;6&#x0005d;</xref> These abnormalities lead to chronic bacterial infection, which is the key factor in the morbidity and mortality of CF lung disease <xref ref-type="bibr" rid="pone.0004270-Gibson1">&#x0005b;7&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0004270-Li1">&#x0005b;8&#x0005d;</xref>; additionally, respiratory viral infections are associated with exacerbation and progression of lung disease. <xref ref-type="bibr" rid="pone.0004270-Wat1">&#x0005b;9&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0004270-Wang1">&#x0005b;10&#x0005d;</xref></p><p>Bacteria and viruses bind to mucins and the cellular glycocalyx of airway epithelia based on their glycosylation patterns<xref ref-type="bibr" rid="pone.0004270-Marionneau1">&#x0005b;11&#x0005d;</xref>; thus, genetically based differences in patterns of glycosylation and microbial binding may increase the likelihood of airway infection, and contribute to progression of airway damage, and severity of lung disease. One cause of variability in glycosylation of airway epithelia is inherited blood type, which reflects genetic-based differences in glycosylation enzymes. The histo-blood group antigens, ABO, H, and Lewis, are formed by the action of glycosyltransferases to attach sugar molecules to disaccharide precursors. (See Supplement <xref ref-type="supplementary-material" rid="pone.0004270.s001">Text S1</xref> and <xref ref-type="supplementary-material" rid="pone.0004270.s002">Figure S1</xref>.) Addition of fucose to these disaccharide precursors creates the H antigen, and further modification to the H antigen by glycosyltransferases leads to synthesis of the blood group antigens encoded by the ABO (&#x0201c;blood type&#x0201d;) gene. The O allele does not produce an active enzyme. <xref ref-type="bibr" rid="pone.0004270-Yip1">&#x0005b;12&#x0005d;</xref></p><p>Formation of other histo-blood group antigens is dependent on fucosyltransferases. The FUT2 &#x0201c;secretor&#x0201d; gene encodes the fucosyltransferase that synthesizes the H antigen. Loss-of-function mutations in FUT2 (secretor gene) lead to an absence of ABH antigens in the lung, saliva, and gut, resulting in the &#x0201c;non-secretor&#x0201d; phenotype. Loss-of-function mutations in the FUT3 (Lewis) gene result in the Lewis negative phenotype. <xref ref-type="bibr" rid="pone.0004270-Marionneau1">&#x0005b;11&#x0005d;</xref></p><p>The ABO gene is highly polymorphic, which is thought to be related to evolutionary changes for host-pathogen interactions, as many pathogens utilize surface glycoproteins in host invasion. <xref ref-type="bibr" rid="pone.0004270-Marionneau1">&#x0005b;11&#x0005d;</xref> There is correlation with ABH status and infection with bacteria and viruses; for example, numerous studies have shown that the binding and infection of humans with noroviruses (previously Norwalk virus,) is dependent on ABO and secretor phenotype. <xref ref-type="bibr" rid="pone.0004270-Huang1">&#x0005b;13&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0004270-Marionneau2">&#x0005b;14&#x0005d;</xref> Furthermore, certain strains of <italic>S. aureus</italic> bind to the Lewis antigen <xref ref-type="bibr" rid="pone.0004270-Saadi1">&#x0005b;15&#x0005d;</xref>, and <italic>P. aeruginosa</italic> has a lectin, PA-IIL, that is fucose-specific. <xref ref-type="bibr" rid="pone.0004270-Wu1">&#x0005b;16&#x0005d;</xref> Thus, genetic-based differences in glycosylation that determine blood type can also predispose to an increased likelihood of bacterial and/or viral binding and infection in the airways. Additionally, polymorphisms in the genes coding for the ABH antigens are associated with airway diseases, including COPD and asthma. <xref ref-type="bibr" rid="pone.0004270-Cohen1">&#x0005b;17&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0004270-Kauffmann1">&#x0005b;18&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0004270-Ronchetti1">&#x0005b;19&#x0005d;</xref></p><p>We speculated that genetic predisposition to different patterns of glycosylation in the ABH pathway would lead to early chronic lung infection in CF, and therefore, more severe progression of disease. We tested the genotype of key (ABH) glycosylation enzymes in CF patients with &#x0201c;severe&#x0201d; versus &#x0201c;mild&#x0201d; lung disease, and tested for associations with age of onset of infection with <italic>P. aeruginosa.</italic></p></sec><sec sec-type="methods" id="s2"><title>Methods</title><sec id="s2a"><title>Objectives</title><list list-type="order"><list-item><p>Establish ABO, FUT2 and FUT3 genotype for each subject</p></list-item><list-item><p>Determine whether differences in ABH type predict differences in lung phenotype.</p></list-item></list><p>We hypothesized that subjects with ABH types with more glycosylation (i.e. blood groups A, and B, and secretor and Lewis positive phenotypes) would be more likely to have severe lung phenotype as a result of having an increased predisposition to early viral/bacterial infection.</p></sec><sec id="s2b"><title>Participants</title><p>Patients with Cystic Fibrosis homozygous for the &#x00394;F508 CF gene mutation were enrolled from 44 sites (n&#x0200a;&#x0003d;&#x0200a;808 patients) as previously published. <xref ref-type="bibr" rid="pone.0004270-Drumm1">&#x0005b;20&#x0005d;</xref> Patients were enrolled based on FEV<sub>1</sub> values in the lowest quartile (&#x0201c;severe;&#x0201d; n&#x0200a;&#x0003d;&#x0200a;263) or highest quartile (&#x0201c;mild;&#x0201d; n&#x0200a;&#x0003d;&#x0200a;545) for age. FEV<sub>1</sub> data has been analyzed according to biostatistical models based on longitudinal lung function (FEV<sub>1.</sub>) This modeling has robust power to predict survival; hence the use of multiple spirometric values is a strong surrogate for long-term outcomes. <xref ref-type="bibr" rid="pone.0004270-Schluchter1">&#x0005b;21&#x0005d;</xref></p></sec><sec id="s2c"><title>Description of Procedures</title><sec id="s2c1"><title>Data Collection</title><p>Each patient received a unique identifier code to maintain confidentiality. Source documents were collected for pulmonary function tests, meconium ileus history and sputum microbiology. Case report forms were used to collect information about the presence of diabetes mellitus, steroid use, oral hypoglycemic and insulin use.</p></sec><sec id="s2c2"><title>Source of DNA</title><p>Whole blood in sodium citrate (for DNA extraction) and heparinized (for lymphocyte transformation) tubes was collected from all patients at the time of study enrollment. DNA was extracted and stored using standard methodology in the central molecular pathology facility at University of North Carolina-Chapel Hill (UNC) Hospitals. DNA and transformed lymphocytes were stored frozen in two different storage containers at two separate sites with continuous monitoring.</p></sec><sec id="s2c3"><title>ABO Genotyping</title><p>Sequence variation in 7 ABO alleles accounts for &#x0003e;90&#x00025; of the variants in white Europeans. <xref ref-type="bibr" rid="pone.0004270-Yip1">&#x0005b;12&#x0005d;</xref> Primers were designed to amplify three fragments from exons 6 and 7 containing the 9 SNPs (rs8176719, rs8176720, rs1053878, rs7853989, rs8176740, rs8176741, rs8176742, rs816750, rs8176472) necessary to identify blood type. (See Supplement <xref ref-type="supplementary-material" rid="pone.0004270.s001">Text S1</xref> and <xref ref-type="supplementary-material" rid="pone.0004270.s004">Table S1</xref> for primer sequences.) PCR was performed using standard techniques, and high throughput sequencing was performed on an ABI Prism&#x000ae; 3730 Genetic Analyzer. Batch data analysis was performed with SNP finding via the Polyphred&#x000a9; program. (See Supplement <xref ref-type="supplementary-material" rid="pone.0004270.s001">Text S1</xref> and <xref ref-type="supplementary-material" rid="pone.0004270.s005">Table S2</xref> for sequence variation information used to construct ABO phenotype.)</p></sec><sec id="s2c4"><title>FUT2 Genotyping</title><p>Loss of function mutations in FUT2 (non-secretor) occur in 20&#x00025; of European-derived Caucasians. In Caucasians, one nonsynonymous SNP in FUT2 (G428A, rs601338) accounts for &#x0003e;95&#x00025; of the incidence of nonsecretor phenotype. <xref ref-type="bibr" rid="pone.0004270-Svensson1">&#x0005b;22&#x0005d;</xref> Allele identification was performed using an ABI Taqman&#x000a9; assay on an ABI Prism&#x000ae; 7700HT/7900HT Sequence Detection System.</p></sec><sec id="s2c5"><title>FUT3 Genotyping</title><p>Loss of function mutations in FUT3 (Lewis negative) occur in 10&#x00025; of European-derived Caucasians. SNPs in four positions (T59G, rs28362459; T202C, rs812936; C314T, rs778986; and T1067A, rs3894326) account for 90&#x02013;95&#x00025; of Lewis status in Caucasians. <xref ref-type="bibr" rid="pone.0004270-Salomaa1">&#x0005b;23&#x0005d;</xref> Primers were designed for PCR amplification, and sequencing of the FUT3 gene was performed on an ABI Prism&#x000ae; 3130xl/310 Genetic Analyzer. <xref ref-type="bibr" rid="pone.0004270-Cameron1">&#x0005b;24&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0004270-Pang1">&#x0005b;25&#x0005d;</xref></p></sec><sec id="s2c6"><title>Acquisition of <italic>P. aeruginosa</italic></title><p>In addition to lung function data, all available CFF registry data on study subjects that related to respiratory tract (oropharyngeal and sputum) cultures was acquired. Age of onset of persistent <italic>P. aeruginosa</italic> infection for all patients was established with available culture data (n&#x0200a;&#x0003d;&#x0200a;674), and defined as the first age at which <italic>P. aeruginosa</italic> was present in respiratory cultures in two consecutive, or two out of three years.</p></sec><sec id="s2c7"><title>Ethics</title><p>This study was approved by Institutional Review Boards at all participating institutions. Each participant provided written informed consent prior to study participation. The study is registered in the ClinicalTrials.gov database: NCT00037765.</p></sec><sec id="s2c8"><title>Statistical Methods</title><p>To test for associations between severity of lung disease, key clinical phenotypes, and polymorphisms in ABH genotypes, Fisher's exact test was used. All tests were two-sided. To investigate the effect of blood group alleles (ABO genotype, nonsecretor phenotype, and FUT3 genotypes producing Lewis negative phenotypes) on CF lung severity risk, we performed multiple logistic regression analyses to predict severity status. The number of A and B antigen alleles was included in an additive model on the log-odds of severe lung status, as well as the FUT2 and FUT3 genotypes, and terms to account for possible interaction between the genes. In addition, the following predictors were used in the model: gender, meconium ileus, asthma, and the TGFb1 codon 10 CC genotype (previously shown to be associated with severe lung disease.) In order to determine whether ABH type influenced the age of acquisition of <italic>P. aeruginosa</italic>, Kaplan-Meier analysis was performed using SigmaStat&#x000ae; software. ABO type, and secretor and Lewis status were evaluated in the mild versus severe groups. Additionally, to address the possibility of age confounding the analysis of <italic>P. aeruginosa</italic> acquisition, ABH types were also analyzed in the severe group versus the group of mild patients who were aged 15&#x02013;28 years (&#x0201c;young milds,&#x0201d;) and interactions among the three ABH types were analyzed. Allelic comparison that yielded a statistical significance of &#x02264;0.05 was considered significant. Unadjusted p-values are reported.</p></sec></sec></sec><sec id="s3"><title>Results</title><sec id="s3a"><title>Characteristics of the patients</title><p>As previously reported, pulmonary and nutrition characteristics of the patients classified as severe (n&#x0200a;&#x0003d;&#x0200a;263) were markedly different than that of patients classified as mild (n&#x0200a;&#x0003d;&#x0200a;545.) <xref ref-type="bibr" rid="pone.0004270-Drumm1">&#x0005b;20&#x0005d;</xref> Although the mean age of the patients in the mild group was 28.6 &#x000b1; 9.7 years compared to 16.2 &#x000b1; 4.2 years in the severe group, FEV<sub>1</sub> was more than 25&#x00025; higher and body mass index percentile was 24&#x00025; higher in the patients in the mild group versus those in the severe group (p&#x0003c;0.001). Gender, prevalence of diabetes mellitus (adjusted for age), and asthma were similar between patients in the mild and severe groups. <xref ref-type="bibr" rid="pone.0004270-Drumm1">&#x0005b;20&#x0005d;</xref></p></sec><sec id="s3b"><title>ABO genotype</title><p>ABO genotype was successfully determined for 778 patients. ABO allele frequencies, and resultant ABO blood groups were consistent with the reported prevalence in the Caucasian population. <xref ref-type="bibr" rid="pone.0004270-Harmening1">&#x0005b;26&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0004270-dbSNP1">&#x0005b;27&#x0005d;</xref> (See Supplement <xref ref-type="supplementary-material" rid="pone.0004270.s001">Text S1</xref> and <xref ref-type="supplementary-material" rid="pone.0004270.s006">Table S3</xref>.) We saw no significant difference in blood type distribution between mild and severe patients by Fisher exact test. (p&#x0200a;&#x0003d;&#x0200a;0.446). (<xref ref-type="table" rid="pone-0004270-t001">Table 1</xref>) We also saw no significant associations when ABO allele distribution was analyzed in the following subgroups: males and females, patients with and without asthma, and patients with and without history of meconium ileus. (Data not shown.)</p><table-wrap id="pone-0004270-t001" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0004270.t001</object-id><label>Table 1</label><caption><title>Prevalence of ABO blood types in severe and mild patient groups.</title></caption><graphic id="pone-0004270-t001-1" xlink:href="pone.0004270.t001"/><table frame="hsides" rules="groups" alternate-form-of="pone-0004270-t001-1"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup><thead><tr><td align="left" rowspan="1" colspan="1">Blood type</td><td align="left" rowspan="1" colspan="1">Severe Group</td><td align="left" rowspan="1" colspan="1">Mild Group</td></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1"><bold>O</bold></td><td align="left" rowspan="1" colspan="1">127 (50.8&#x00025;)</td><td align="left" rowspan="1" colspan="1">243 (46.2&#x00025;)</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>B</bold></td><td align="left" rowspan="1" colspan="1">21 (8.3&#x00025;)</td><td align="left" rowspan="1" colspan="1">62 (11.8&#x00025;)</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>A</bold></td><td align="left" rowspan="1" colspan="1">94 (37.3&#x00025;)</td><td align="left" rowspan="1" colspan="1">202 (38.4&#x00025;)</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>AB</bold></td><td align="left" rowspan="1" colspan="1">9 (3.6&#x00025;)</td><td align="left" rowspan="1" colspan="1">19 (3.6&#x00025;)</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">252</td><td align="left" rowspan="1" colspan="1">526</td></tr></tbody></table><table-wrap-foot><fn id="nt101"><p>ABO allele frequencies and resultant ABO phenotypes were consistent with known prevalence in the Caucasian population. <xref ref-type="bibr" rid="pone.0004270-Harmening1">&#x0005b;26&#x0005d;</xref> There is no significant difference in blood type distribution amongst mild and severe patients, or in any subgroup analysis (see <xref ref-type="supplementary-material" rid="pone.0004270.s001">Text S1</xref>) by Fisher exact test. (n&#x0200a;&#x0003d;&#x0200a;778, p&#x0200a;&#x0003d;&#x0200a;0.446)</p></fn></table-wrap-foot></table-wrap></sec><sec id="s3c"><title>FUT2 genotype</title><p>FUT2 (&#x0201c;secretor/nonsecretor&#x0201d;) alleles for SNP G428A (rs601338) were successfully determined in 806 patients. The distribution of alleles was consistent with that found in the Caucasian population. <xref ref-type="bibr" rid="pone.0004270-dbSNP1">&#x0005b;27&#x0005d;</xref> There was no significant difference in secretor status distribution between mild and severe patients by Fisher exact test (p&#x0200a;&#x0003d;&#x0200a;0.569). (<xref ref-type="table" rid="pone-0004270-t002">Table 2</xref>) Subgroup analysis by gender, asthma and meconium ileus status did not reveal any associations. (<xref ref-type="table" rid="pone-0004270-t002">Table 2</xref>)</p><table-wrap id="pone-0004270-t002" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0004270.t002</object-id><label>Table 2</label><caption><title>Prevalence of FUT2 and FUT3 alleles and genotypes in severe and mild patient groups.</title></caption><graphic id="pone-0004270-t002-2" xlink:href="pone.0004270.t002"/><table frame="hsides" rules="groups" alternate-form-of="pone-0004270-t002-2"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup><thead><tr><td align="left" rowspan="1" colspan="1">Gene</td><td align="left" rowspan="1" colspan="1">Variant</td><td align="left" rowspan="1" colspan="1">Reference SNP</td><td align="left" rowspan="1" colspan="1">Impairment of lung function</td><td align="left" rowspan="1" colspan="1">Genotype</td><td align="left" rowspan="1" colspan="1">Patients with genotype</td><td align="left" rowspan="1" colspan="1">Genotype</td><td align="left" rowspan="1" colspan="1">Patients with genotype</td><td align="left" rowspan="1" colspan="1">Genotype</td><td align="left" rowspan="1" colspan="1">Patients with genotype</td><td align="left" rowspan="1" colspan="1">Number of Patients</td><td align="left" rowspan="1" colspan="1">P-Value&#x000a7;</td></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">FUT2 (Secretor gene)</td><td align="left" rowspan="1" colspan="1">G428A</td><td align="left" rowspan="1" colspan="1">rs601338</td><td align="left" rowspan="1" colspan="1">Mild</td><td align="left" rowspan="1" colspan="1">AA</td><td align="left" rowspan="1" colspan="1">137(24.3&#x00025;)</td><td align="left" rowspan="1" colspan="1">AG</td><td align="left" rowspan="1" colspan="1">273 (54.0&#x00025;)</td><td align="left" rowspan="1" colspan="1">GG</td><td align="left" rowspan="1" colspan="1">134 (21.6&#x00025;)</td><td align="left" rowspan="1" colspan="1">544</td><td align="left" rowspan="1" colspan="1">0.569</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Severe</td><td align="left" rowspan="1" colspan="1">AA</td><td align="left" rowspan="1" colspan="1">57 (21.8&#x00025;)</td><td align="left" rowspan="1" colspan="1">AG</td><td align="left" rowspan="1" colspan="1">137 (52.3&#x00025;)</td><td align="left" rowspan="1" colspan="1">GG</td><td align="left" rowspan="1" colspan="1">68 (26.0&#x00025;)</td><td align="left" rowspan="1" colspan="1">262</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">FUT3 (Lewis gene)</td><td align="left" rowspan="1" colspan="1">T59G</td><td align="left" rowspan="1" colspan="1">rs28362459</td><td align="left" rowspan="1" colspan="1">Mild</td><td align="left" rowspan="1" colspan="1">TT</td><td align="left" rowspan="1" colspan="1">389 (84.0&#x00025;)</td><td align="left" rowspan="1" colspan="1">TG</td><td align="left" rowspan="1" colspan="1">71 (15.6&#x00025;)</td><td align="left" rowspan="1" colspan="1">GG</td><td align="left" rowspan="1" colspan="1">3 (1.2&#x00025;)</td><td align="left" rowspan="1" colspan="1">463</td><td align="left" rowspan="1" colspan="1">0.554</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Severe</td><td align="left" rowspan="1" colspan="1">TT</td><td align="left" rowspan="1" colspan="1">208 (82.2&#x00025;)</td><td align="left" rowspan="1" colspan="1">TG</td><td align="left" rowspan="1" colspan="1">43 (16.9&#x00025;)</td><td align="left" rowspan="1" colspan="1">GG</td><td align="left" rowspan="1" colspan="1">3 (1.2&#x00025;)</td><td align="left" rowspan="1" colspan="1">254</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">T202C</td><td align="left" rowspan="1" colspan="1">rs812936</td><td align="left" rowspan="1" colspan="1">Mild</td><td align="left" rowspan="1" colspan="1">TT</td><td align="left" rowspan="1" colspan="1">318 (66.1&#x00025;)</td><td align="left" rowspan="1" colspan="1">TC</td><td align="left" rowspan="1" colspan="1">127 (30.3&#x00025;)</td><td align="left" rowspan="1" colspan="1">CC</td><td align="left" rowspan="1" colspan="1">18 (3.47&#x00025;)</td><td align="left" rowspan="1" colspan="1">463</td><td align="left" rowspan="1" colspan="1">0.491</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Severe</td><td align="left" rowspan="1" colspan="1">TT</td><td align="left" rowspan="1" colspan="1">168 (66.1&#x00025;)</td><td align="left" rowspan="1" colspan="1">TC</td><td align="left" rowspan="1" colspan="1">79 (31.1&#x00025;)</td><td align="left" rowspan="1" colspan="1">CC</td><td align="left" rowspan="1" colspan="1">7 (2.8&#x00025;)</td><td align="left" rowspan="1" colspan="1">254</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">C314T</td><td align="left" rowspan="1" colspan="1">rs778986</td><td align="left" rowspan="1" colspan="1">Mild</td><td align="left" rowspan="1" colspan="1">CC</td><td align="left" rowspan="1" colspan="1">321 (66.5&#x00025;)</td><td align="left" rowspan="1" colspan="1">CT</td><td align="left" rowspan="1" colspan="1">126 (30.4&#x00025;)</td><td align="left" rowspan="1" colspan="1">TT</td><td align="left" rowspan="1" colspan="1">16 (3.1&#x00025;)</td><td align="left" rowspan="1" colspan="1">463</td><td align="left" rowspan="1" colspan="1">0.615</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Severe</td><td align="left" rowspan="1" colspan="1">CC</td><td align="left" rowspan="1" colspan="1">172 (67.7&#x00025;)</td><td align="left" rowspan="1" colspan="1">CT</td><td align="left" rowspan="1" colspan="1">76 (29.9&#x00025;)</td><td align="left" rowspan="1" colspan="1">TT</td><td align="left" rowspan="1" colspan="1">6 (2.4&#x00025;)</td><td align="left" rowspan="1" colspan="1">254</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">T1067A</td><td align="left" rowspan="1" colspan="1">rs3894326</td><td align="left" rowspan="1" colspan="1">Mild</td><td align="left" rowspan="1" colspan="1">TT</td><td align="left" rowspan="1" colspan="1">420 (90.4&#x00025;)</td><td align="left" rowspan="1" colspan="1">TA</td><td align="left" rowspan="1" colspan="1">43 (9.64&#x00025;)</td><td align="left" rowspan="1" colspan="1">AA</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">463</td><td align="left" rowspan="1" colspan="1">0.792</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Severe</td><td align="left" rowspan="1" colspan="1">TT</td><td align="left" rowspan="1" colspan="1">229 (90.2&#x00025;)</td><td align="left" rowspan="1" colspan="1">TA</td><td align="left" rowspan="1" colspan="1">25 (9.8&#x00025;)</td><td align="left" rowspan="1" colspan="1">AA</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">254</td><td align="left" rowspan="1" colspan="1"/></tr></tbody></table><table-wrap-foot><fn id="nt102"><p>FUT2 and FUT3 allele frequencies and genotypes, and resultant phenotypes were consistent with that known for the Caucasian population. <xref ref-type="bibr" rid="pone.0004270-dbSNP1">&#x0005b;27&#x0005d;</xref> There is no association between lung disease severity in patients homozygous for the &#x00394;F508 mutation and individual FUT2 or FUT 3 SNPs, nor with secretor or Lewis status. <sup>&#x000a7;</sup> P-values generated by Fisher exact test.</p></fn></table-wrap-foot></table-wrap></sec><sec id="s3d"><title>FUT3 genotype</title><p>Four SNPs account for 90&#x02013;95&#x00025; of Lewis status in Caucasians. <xref ref-type="bibr" rid="pone.0004270-Salomaa1">&#x0005b;23&#x0005d;</xref> FUT 3 alleles were successfully determined at these four loci for 707 patients. There was no significant difference for individual SNPs between mild versus severe lung disease patients, nor by gender, meconium ileus or asthma status by Fisher exact test. (See <xref ref-type="table" rid="pone-0004270-t002">Table 2</xref>.) Orntoft et al correlated FUT3 gene mutations with enzyme activity and circulating levels of sialyl-Lewis a <xref ref-type="bibr" rid="pone.0004270-Orntoft1">&#x0005b;28&#x0005d;</xref>; therefore, the SNPs were analyzed in groups consistent with Lewis negative or positive phenotypes, but no significant differences were observed. (Data not shown.) <xref ref-type="bibr" rid="pone.0004270-Salomaa1">&#x0005b;23&#x0005d;</xref></p></sec><sec id="s3e"><title>ABH Type</title><p>We anticipated that the A, B or AB blood group, secretor (FUT2) and Lewis positive (FUT3) genotypes would be found in higher prevalence in patients with severe lung phenotype, because genotypes associated with functional fucosyltransferases for synthesis of pertinent glycoproteins have been shown to be associated with increased propensity towards infection with <italic>P. aeruginosa</italic>, <italic>H. influenzae</italic> and <italic>S. aureus</italic>. <xref ref-type="bibr" rid="pone.0004270-Saadi1">&#x0005b;15&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0004270-Rhim1">&#x0005b;29&#x0005d;</xref> Conversely, we thought that O blood group, non-secretor and Lewis negative genotypes (genotypes that lack or produce nonfunctional fucosyltransferases) would have higher prevalence in patients with mild phenotypes, reflecting a reduced risk of infection. In order to evaluate the effect of ABH type (A, B, AB, or O blood type, secretor status, and Lewis status) on risk for severe lung disease, multiple logistic regression was performed using the severity phenotype as a response, and the ABH type variables as predictors. Neither main effects nor interactions of ABH genotypes achieved marginal significance at level alpha&#x0200a;&#x0003d;&#x0200a;0.10. (See Supplement <xref ref-type="supplementary-material" rid="pone.0004270.s001">Text S1</xref> and <xref ref-type="supplementary-material" rid="pone.0004270.s007">Table S4</xref>.)</p></sec><sec id="s3f"><title>Acquisition of <italic>P. aeruginosa</italic> and ABH Type</title><p>By age 18, up to 80&#x00025; of CF patients are colonized with <italic>P. aeruginosa.</italic><xref ref-type="bibr" rid="pone.0004270-Gibson1">&#x0005b;7&#x0005d;</xref> Thus, in our population of patients, there was no significant difference between <italic>P. aeruginosa</italic> colonization in the mild versus the severe groups at the age of enrollment (mean age 28.6&#x000b1;9.7 years and 16.2&#x000b1;4.1 years, respectively.) In order to determine if ABH status was associated with early infection with <italic>P. aeruginosa,</italic> data from the national CFF Registry was used to determine age of first acquisition of <italic>P. aeruginosa</italic> for each patient (as defined in <xref ref-type="sec" rid="s2">Methods</xref>.) So that the question could be examined in a groups of patients that were similar in age for this comparison, data from both the entire mild group, and from a subset of the mild group (&#x0201c;young milds,&#x0201d; age 15&#x02013;28 years with a mean age of 20.9&#x000b1;4.0 years) was used. A clear distinction was noted in the age of onset for persistent <italic>P. aeruginosa</italic> infection (age 6.9 years in the severe group, n&#x0200a;&#x0003d;&#x0200a;194 versus age12.4 years in the young mild group, n&#x0200a;&#x0003d;&#x0200a;224 p&#x0003c;0.0001) <xref ref-type="bibr" rid="pone.0004270-PittmanJ1">&#x0005b;30&#x0005d;</xref> Complete data (at least 3 years of <italic>P. aeruginosa</italic> culture data available to define persistent infection, and information for at least one of the three ABH genotypes) was available on 661 patients. Associations between ABO, secretor and Lewis phenotypes and <italic>P. aeruginosa</italic> acquisition were analyzed by Kaplan-Meir plots for patients in the severe group, for patients in the entire mild group, and for patients in the young mild group. No significant differences for ABO blood group, secretor versus non-secretor status, or Lewis positive versus Lewis negative status were observed within groups. Furthermore, no significant differences were seen between patients in the severe group compared to those in the mild group nor in the young mild group based on ABH status. (<xref ref-type="fig" rid="pone-0004270-g001">Figure 1</xref>; for simplicity, combined data for patients in the severe and young mild groups is shown. Individual plots for the severe and young mild groups are shown in Supplement <xref ref-type="supplementary-material" rid="pone.0004270.s001">Text S1</xref> and <xref ref-type="supplementary-material" rid="pone.0004270.s003">Figure S2</xref>.)</p><fig id="pone-0004270-g001" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0004270.g001</object-id><label>Figure 1</label><caption><title>Association between age of onset of persistent <italic>P. aeruginosa</italic> infection and ABH type.</title><p>Kaplan-Meir curves were generated (includes exit censoring) to test associations between ABH and age of onset of <italic>P. aeruginosa</italic> infection in the respiratory tract for patients with mild and severe disease. (For simplicity, figures show the proportion of infected patients in the combined group of young mild and severe patients for whom culture and ABH genotype data was available.) A) ABO blood group, B) Secretor phenotype and C) Lewis phenotype. No significant differences were seen.</p></caption><graphic xlink:href="pone.0004270.g001"/></fig></sec></sec><sec id="s4"><title>Discussion</title><p>Although a great deal is known about the pathophysiology of CF lung disease, and more than 1500 CF mutations have been described <xref ref-type="bibr" rid="pone.0004270-Cohen1">&#x0005b;17&#x0005d;</xref>, predictable correlation between CFTR genotype and lung phenotype has not been established. <xref ref-type="bibr" rid="pone.0004270-Rowntree1">&#x0005b;31&#x0005d;</xref> Furthermore, it is known that patients with the same CF gene mutations can have highly variable outcomes. <xref ref-type="bibr" rid="pone.0004270-Kerem1">&#x0005b;32&#x0005d;</xref> Two studies of CF twins and siblings have shown that most of the disease variation reflects genetic rather than environmental influences <xref ref-type="bibr" rid="pone.0004270-Vanscoy1">&#x0005b;33&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0004270-Khan1">&#x0005b;34&#x0005d;</xref>; thus, multiple studies are investigating what non-CF genes may play a role in CF phenotype. <xref ref-type="bibr" rid="pone.0004270-Drumm1">&#x0005b;20&#x0005d;</xref></p><p>We chose to evaluate the ABH genes as candidates for modifiers of CF lung disease severity because the role postulated for these polymorphic genes coding for the ABH antigens is thought to be related to host-pathogen interactions; specifically, many pathogens utilize surface glycoproteins in host invasion. Numerous studies have shown that the binding and infection of humans with microbial organisms is dependent on ABH status; for example, noroviruses (previously Norwalk virus,) certain strains of <italic>S. aureus, H. influenzae, and P. aeruginosa</italic> have this capability. <xref ref-type="bibr" rid="pone.0004270-Huang1">&#x0005b;13&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0004270-Marionneau2">&#x0005b;14&#x0005d;</xref> Polymorphisms in the genes coding for the ABH antigens are also known to be associated with various disease states, including pulmonary disease. <xref ref-type="bibr" rid="pone.0004270-Marionneau1">&#x0005b;11&#x0005d;</xref> Patients with COPD who are nonsecretors had significantly lower mean FEV<sub>1</sub>/FVC values than secretors, suggesting that the presence of ABH antigens in respiratory epithelium may be protective in COPD. <xref ref-type="bibr" rid="pone.0004270-Cohen1">&#x0005b;17&#x0005d;</xref> Similarly, Lewis negative or nonsecretor status was significantly associated with lower lung function, and higher prevalence of wheezing and asthma, in blood group O adults. <xref ref-type="bibr" rid="pone.0004270-Kauffmann1">&#x0005b;18&#x0005d;</xref> The association between blood group O/nonsecretor genotype and asthma has also been demonstrated in children. <xref ref-type="bibr" rid="pone.0004270-Ronchetti1">&#x0005b;19&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0004270-Khan1">&#x0005b;34&#x0005d;</xref> One small study was performed in fifty patients with CF to evaluate whether secretor status was a risk factor for clinical status or <italic>P. aeruginosa</italic> or <italic>S. aureus</italic> colonization. The study found no correlation between secretor status and the clinical variables examined; however, it may have been significantly underpowered to detect a difference with only 17 patients in the nonsecretor group. <xref ref-type="bibr" rid="pone.0004270-Haponik1">&#x0005b;35&#x0005d;</xref></p><p>Based on previous studies demonstrating an association between ABH genotype and predisposition to infection and lung disease <xref ref-type="bibr" rid="pone.0004270-Shori1">&#x0005b;36&#x0005d;</xref>, we hypothesized that ABH type might affect lung severity in CF, and genotyped approximately 800 CF patients for ABH type. Although the whole genome scan approach will be used in future genetic modifier studies, the candidate gene approach was chosen to test our hypothesis as only two of the relevant ABH SNPs are included on current SNP-based whole genome platforms.</p><p>We examined the ABO, secretor and Lewis status individually in the severe versus mild CF lung disease groups, and found no difference in prevalence of each ABH type between the two groups.</p><p>The knowledge that lung disease severity may result from a multitude of other genetic and environmental factors also lead us to hypothesize that more specific phenotypes should be examined for association with ABH genotype, such as female gender, which is associated with worse outcome in CF. <xref ref-type="bibr" rid="pone.0004270-Zemel1">&#x0005b;37&#x0005d;</xref> Therefore, we evaluated the prevalence of ABH genotypes in males versus females, but no association was found in our CF population.</p><p>Although approximately 80&#x00025; of patients develop chronic Pseudomonal infection by early adulthood, the age of acquisition of <italic>P. aeruginosa</italic> is variable. <xref ref-type="bibr" rid="pone.0004270-Li1">&#x0005b;8&#x0005d;</xref> Based on previous studies demonstrating increased susceptibility to <italic>P. aeruginosa</italic> based on ABH group <xref ref-type="bibr" rid="pone.0004270-Wu1">&#x0005b;16&#x0005d;</xref>, and increased affinity of <italic>P. aeruginosa</italic> for CF respiratory and salivary mucins <xref ref-type="bibr" rid="pone.0004270-Shori1">&#x0005b;36&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0004270-Imundo1">&#x0005b;38&#x0005d;</xref>&#x02013;<xref ref-type="bibr" rid="pone.0004270-Komiyama1">&#x0005b;41&#x0005d;</xref>, we hypothesized that there would be a difference in prevalence of the ABH antigens amongst those patients with earlier colonization with <italic>P. aeruginosa</italic>. However, there was no difference in prevalence of ABO, secretor or Lewis genotypes associated with age of onset of persistent <italic>P. aeruginosa</italic> whether we looked at all patients, or restricted our analysis to the severe group or to the mild group.</p><p>Another phenotype considered was that of meconium ileus (MI). It is known that only 15&#x02013;20&#x00025; of CF patients, regardless of CF gene mutation, develop MI. Previous studies of ileal mucus in CF neonates with MI have demonstrated increased fucosylation. <xref ref-type="bibr" rid="pone.0004270-Clamp1">&#x0005b;42&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0004270-Thiru1">&#x0005b;43&#x0005d;</xref> CF gene knockout mice, whose main pathology is intestinal mucous obstruction, have increased fucosylation and increased FUT2 expression.<xref ref-type="bibr" rid="pone.0004270-Thomsson1">&#x0005b;44&#x0005d;</xref> In a small study of homo- and heterozygous &#x00394;F508 patients, presence of both functional secretor and Lewis genes was associated with meconium ileus. <xref ref-type="bibr" rid="pone.0004270-Elmgren1">&#x0005b;45&#x0005d;</xref> These studies lead us to hypothesize that MI in CF patients may be related to glycosylation patterns/ABH status; however, no difference in prevalence of ABH genotypes was found between the two groups. Because there are only 129 patients in the MI group, this evaluation may be under powered to detect a difference.</p><sec id="s4a"><title>Limitations</title><p>Bacterial colonization and inflammation may appear very early in CF lung disease <xref ref-type="bibr" rid="pone.0004270-Khan1">&#x0005b;34&#x0005d;</xref>, and prospective cultures were not available; we recognize the limitation of data collected retrospectively for <italic>P. aeruginosa</italic> acquisition and infection. However, we were able to collect culture data on more than 60&#x00025; of these patients by age 8 years; 73&#x00025; of the patients with mild disease and 60&#x00025; of patients with severe disease were culture negative for <italic>P. aeruginosa</italic> at the time of first available culture. Thus, our sample should be adequate to answer the question. However, if ABH genotypes predispose to early bacterial or viral infection, it is possible that we were unable to demonstrate this finding in our group of older children and adults. To definitively determine if there is an effect of differences in ABH genotype on early acquisition of infection and subsequent lung health in CF, it would be necessary to prospectively study this question.</p><p>In general, the loss of some patients from an original birth cohort is a limitation to study designs examining variants in severe versus mild forms of the disease. However, according to CF registry data, for the cohort we examined, only 10&#x00025; have died by age 16 years, thus, there were relatively few deaths in our cohort. Additionally, the patients in our cohort classified as having severe lung disease are still in the worst 25<sup>th</sup> percentile for their birth cohort, and the patients with mild disease are in the upper 25<sup>th</sup> percentile of their birth cohort. The validity of these concepts has previously been demonstrated; we reported that <italic>TGFB</italic> genotype is associated with disease severity, and this finding has been replicated in two additional cohorts. <xref ref-type="bibr" rid="pone.0004270-Drumm1">&#x0005b;20&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0004270-Bremer1">&#x0005b;46&#x0005d;</xref> Thus, while death of the most severe patients could have potentially influenced the outcome of this study because of the extremes of phenotype design, we do not believe that limitation is a critical factor in the findings reported here.</p><p>In conclusion, there is a clear association between the age of onset of chronic <italic>P. aeruginosa</italic> infection and the severity of lung disease, but this association was not found to be related to ABH genotype. We found no association between ABO blood group, or secretor or Lewis status with lung disease severity or <italic>P. aeruginosa</italic> infection status in a large group of CF patients homozygous for the &#x00394;F508 mutation. Nor did we find an association between ABH genotype and gender, asthma or meconium ileus in this patient population. This targeted study has generated important &#x0201c;negative&#x0201d; data regarding modifier genes in CF, which is not possible through SNP-based platforms (e.g. Ilumina 550K chip) because these platforms do not test for all of the pertinent SNPs necessary to establish ABO, Secretor and Lewis status.</p></sec></sec><sec sec-type="supplementary-material" id="s5"><title>Supporting Information</title><supplementary-material content-type="local-data" id="pone.0004270.s001"><label>Text S1</label><caption><p>(0.07 MB DOC)</p></caption><media xlink:href="pone.0004270.s001.doc" mimetype="application" mime-subtype="msword"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pone.0004270.s002"><label>Figure S1</label><caption><p>Major pathways of synthesis of the ABH and Lewis antigens (Adapted with permission.) <xref ref-type="bibr" rid="pone.0004270-Boyle1">&#x0005b;5&#x0005d;</xref> Type I is antigen precursor of ABH antigens in secretions. Le-Lewis positive and le&#x0200a;&#x0003d;&#x0200a;Lewis negative. See text for more detail. Lewis a/x denotes addition to Type 1 or Type 2 disaccharide precursor. Lewis b/y denotes addition to H antigen derived from Type 1 or Type 2 disaccharide precursor.</p><p>(0.13 MB PDF)</p></caption><media xlink:href="pone.0004270.s002.pdf" mimetype="application" mime-subtype="pdf"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pone.0004270.s003"><label>Figure S2</label><caption><p>Association between age of onset of persistent P. aeruginosa infection and ABH type. Kaplan-Meir curves were generated (includes exit censoring) to test associations between ABH and age of onset of P. aeruginosa infection in the respiratory tract for patients with mild and severe disease. Figures show the proportion of infected patients in the young mild and severe patients for whom culture and ABH genotype data was available. A) ABO blood group in patients with severe disease, B) ABO blood group in young patients with mild disease, C) Secretor phenotype in patients with severe disease D) Secretor phenotype in young patients with mild disease E) Lewis phenotype in patients with severe disease, F) Lewis phenotype in young patients with mild disease. A marginally significant p-value (p&#x0200a;&#x0003d;&#x0200a;0.032) was demonstrated in secretor status in patients in the severe group. No other significant differences were seen by Log-Rank test. S-Secretor, NS-Nonsecretor</p><p>(3.82 MB TIF)</p></caption><media xlink:href="pone.0004270.s003.tif" mimetype="image" mime-subtype="tiff"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pone.0004270.s004"><label>Table S1</label><caption><p>PCR fragments and primers for ABO genotyping. Primers were designed to amplify three fragments from exons 6 and 7 containing the 9 SNPs (rs8176719, rs8176720, rs1053878, rs7853989, rs8176740, rs8176741, rs8176742, rs816750, rs8176472) necessary to identify blood type.</p><p>(0.02 MB DOC)</p></caption><media xlink:href="pone.0004270.s004.doc" mimetype="application" mime-subtype="msword"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pone.0004270.s005"><label>Table S2</label><caption><p>Sequence variations in the 7 most common ABO alleles. Base changes resulting in sequence variation. Changes are shown with reference to A1. This research was originally published in (3) &#x000a9; the American Society of Hematology.</p><p>(0.03 MB DOC)</p></caption><media xlink:href="pone.0004270.s005.doc" mimetype="application" mime-subtype="msword"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pone.0004270.s006"><label>Table S3</label><caption><p>Reported incidence of ABO, secretor and Lewis phenotypes in the N&#x0200a;&#x0003d;&#x0200a;692. The reported incidence of ABO, secretor and Lewis phenotypes is shown in black. <xref ref-type="bibr" rid="pone.0004270-Gibson1">&#x0005b;7&#x0005d;</xref> Based on our ABH genotyping, the percentage of GMS patients in each category is shown in italics.</p><p>(0.03 MB DOC)</p></caption><media xlink:href="pone.0004270.s006.doc" mimetype="application" mime-subtype="msword"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pone.0004270.s007"><label>Table S4</label><caption><p>Multivariate regression analysis. To investigate the effect of blood group alleles (ABO genotype, nonsecretor phenotype, and FUT3 genotypes producing Lewis negative phenotypes) on CF lung severity risk, we performed multiple logistic regression analyses to predict severity status. As previously reported <xref ref-type="bibr" rid="pone.0004270-Bobadilla1">&#x0005b;1&#x0005d;</xref>, there was a highly statistically significant correlation with the TGF-&#x003b2; codon 10 CC genotype, and a moderately significant association with meconium ileus status. No other variables achieved marginal significance at level alpha&#x0200a;&#x0003d;&#x0200a;0.10, including main effects and interactions of ABH genotypes.</p><p>(0.04 MB DOC)</p></caption><media xlink:href="pone.0004270.s007.doc" mimetype="application" mime-subtype="msword"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material></sec></body><back><ack><p>The authors would like to thank Allison Handler, RN, Michelle Kiser MD, John Yeatts, and Sally Wood for their assistance in collecting phenotype data; Jessica Pittman, MD for assistance in data analysis; Fei Zou PhD for assistance is data analysis; David Schwartz, MD for project mentorship; and David Fargo PhD and Annie Xu MD for assistance with data management.</p></ack><ref-list><title>References</title><ref id="pone.0004270-Bobadilla1"><label>1</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bobadilla</surname><given-names>JL</given-names></name><name><surname>Macek</surname><given-names>M</given-names><suffix>Jr</suffix></name><name><surname>Fine</surname><given-names>JP</given-names></name><name><surname>Farrell</surname><given-names>PM</given-names></name></person-group><year>2002</year><article-title>Cystic fibrosis: a worldwide analysis of CFTR mutations&#x02013;correlation with incidence data and application to screening.</article-title><source>Hum Mutat</source><volume>19</volume><fpage>575</fpage><lpage>606</lpage><pub-id pub-id-type="pmid">12007216</pub-id></citation></ref><ref id="pone.0004270-Riordan1"><label>2</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Riordan</surname><given-names>RJ</given-names><suffix>JR</suffix></name><name><surname>Kerem</surname><given-names>BS</given-names></name><name><surname>Alon</surname><given-names>N</given-names></name><etal/></person-group><year>1989</year><article-title>Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA.</article-title><source>Science</source><volume>245</volume><fpage>1059</fpage><lpage>1065</lpage><pub-id pub-id-type="pmid">2772657</pub-id></citation></ref><ref id="pone.0004270-Cystic1"><label>3</label><citation citation-type="journal">Cystic Fibrosis Mutation Data Base</citation></ref><ref id="pone.0004270-Cutting1"><label>4</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cutting</surname><given-names>GR</given-names></name></person-group><year>2005</year><article-title>Modifier genetics: cystic fibrosis.</article-title><source>Annu Rev Genomics Hum Genet</source><volume>6</volume><fpage>237</fpage><lpage>260</lpage><pub-id pub-id-type="pmid">16124861</pub-id></citation></ref><ref id="pone.0004270-Boyle1"><label>5</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Boyle</surname><given-names>MP</given-names></name></person-group><year>2007</year><article-title>Strategies for identifying modifier genes in cystic fibrosis.</article-title><source>Proc Am Thorac Soc</source><volume>4</volume><fpage>52</fpage><lpage>57</lpage><pub-id pub-id-type="pmid">17202292</pub-id></citation></ref><ref id="pone.0004270-Knowles1"><label>6</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Knowles</surname><given-names>MR</given-names></name><name><surname>Boucher</surname><given-names>RC</given-names></name></person-group><year>2002</year><article-title>Mucus clearance as a primary innate defense mechanism for mammalian airways.</article-title><source>J Clin Invest</source><volume>109</volume><fpage>571</fpage><lpage>577</lpage><pub-id pub-id-type="pmid">11877463</pub-id></citation></ref><ref id="pone.0004270-Gibson1"><label>7</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gibson</surname><given-names>RL</given-names></name><name><surname>Burns</surname><given-names>JL</given-names></name><name><surname>Ramsey</surname><given-names>BW</given-names></name></person-group><year>2003</year><article-title>Pathophysiology and management of pulmonary infections in cystic fibrosis.</article-title><source>Am J Respir Crit Care Med</source><volume>168</volume><fpage>918</fpage><lpage>951</lpage><pub-id pub-id-type="pmid">14555458</pub-id></citation></ref><ref id="pone.0004270-Li1"><label>8</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>Z</given-names></name><name><surname>Kosorok</surname><given-names>MR</given-names></name><name><surname>Farrell</surname><given-names>PM</given-names></name><name><surname>Laxova</surname><given-names>A</given-names></name><name><surname>West</surname><given-names>SE</given-names></name><etal/></person-group><year>2005</year><article-title>Longitudinal development of mucoid Pseudomonas aeruginosa infection and lung disease progression in children with cystic fibrosis.</article-title><source>Jama</source><volume>293</volume><fpage>581</fpage><lpage>588</lpage><pub-id pub-id-type="pmid">15687313</pub-id></citation></ref><ref id="pone.0004270-Wat1"><label>9</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wat</surname><given-names>D</given-names></name><name><surname>Gelder</surname><given-names>C</given-names></name><name><surname>Hibbitts</surname><given-names>S</given-names></name><name><surname>Cafferty</surname><given-names>F</given-names></name><name><surname>Bowler</surname><given-names>I</given-names></name><etal/></person-group><year>2008</year><article-title>The role of respiratory viruses in cystic fibrosis.</article-title><source>J Cyst Fibros</source><volume>7</volume><fpage>320</fpage><lpage>328</lpage><pub-id pub-id-type="pmid">18255355</pub-id></citation></ref><ref id="pone.0004270-Wang1"><label>10</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>EE</given-names></name><name><surname>Prober</surname><given-names>CG</given-names></name><name><surname>Manson</surname><given-names>B</given-names></name><name><surname>Corey</surname><given-names>M</given-names></name><name><surname>Levison</surname><given-names>H</given-names></name></person-group><year>1984</year><article-title>Association of respiratory viral infections with pulmonary deterioration in patients with cystic fibrosis.</article-title><source>N Engl J Med</source><volume>311</volume><fpage>1653</fpage><lpage>1658</lpage><pub-id pub-id-type="pmid">6504106</pub-id></citation></ref><ref id="pone.0004270-Marionneau1"><label>11</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Marionneau</surname><given-names>S</given-names></name><name><surname>Cailleau-Thomas</surname><given-names>A</given-names></name><name><surname>Rocher</surname><given-names>J</given-names></name><name><surname>Le Moullac-Vaidye</surname><given-names>B</given-names></name><name><surname>Ruvoen</surname><given-names>N</given-names></name><etal/></person-group><year>2001</year><article-title>ABH and Lewis histo-blood group antigens, a model for the meaning of oligosaccharide diversity in the face of a changing world.</article-title><source>Biochimie</source><volume>83</volume><fpage>565</fpage><lpage>573</lpage><pub-id pub-id-type="pmid">11522384</pub-id></citation></ref><ref id="pone.0004270-Yip1"><label>12</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Yip</surname><given-names>SP</given-names></name></person-group><year>2002</year><article-title>Sequence variation at the human ABO locus.</article-title><source>Ann Hum Genet</source><volume>66</volume><fpage>1</fpage><lpage>27</lpage><pub-id pub-id-type="pmid">12014997</pub-id></citation></ref><ref id="pone.0004270-Huang1"><label>13</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>P</given-names></name><name><surname>Farkas</surname><given-names>T</given-names></name><name><surname>Marionneau</surname><given-names>S</given-names></name><name><surname>Zhong</surname><given-names>W</given-names></name><name><surname>Ruvoen-Clouet</surname><given-names>N</given-names></name><etal/></person-group><year>2003</year><article-title>Noroviruses bind to human ABO, Lewis, and secretor histo-blood group antigens: identification of 4 distinct strain-specific patterns.</article-title><source>J Infect Dis</source><volume>188</volume><fpage>19</fpage><lpage>31</lpage><pub-id pub-id-type="pmid">12825167</pub-id></citation></ref><ref id="pone.0004270-Marionneau2"><label>14</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Marionneau</surname><given-names>S</given-names></name><name><surname>Airaud</surname><given-names>F</given-names></name><name><surname>Bovin</surname><given-names>NV</given-names></name><name><surname>Le Pendu</surname><given-names>J</given-names></name><name><surname>Ruvoen-Clouet</surname><given-names>N</given-names></name></person-group><year>2005</year><article-title>Influence of the combined ABO, FUT2, and FUT3 polymorphism on susceptibility to Norwalk virus attachment.</article-title><source>J Infect Dis</source><volume>192</volume><fpage>1071</fpage><lpage>1077</lpage><pub-id pub-id-type="pmid">16107962</pub-id></citation></ref><ref id="pone.0004270-Saadi1"><label>15</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Saadi</surname><given-names>AT</given-names></name><name><surname>Weir</surname><given-names>DM</given-names></name><name><surname>Poxton</surname><given-names>IR</given-names></name><name><surname>Stewart</surname><given-names>J</given-names></name><name><surname>Essery</surname><given-names>SD</given-names></name><etal/></person-group><year>1994</year><article-title>Isolation of an adhesin from Staphylococcus aureus that binds Lewis a blood group antigen and its relevance to sudden infant death syndrome.</article-title><source>FEMS Immunol Med Microbiol</source><volume>8</volume><fpage>315</fpage><lpage>320</lpage><pub-id pub-id-type="pmid">8061655</pub-id></citation></ref><ref id="pone.0004270-Wu1"><label>16</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>AM</given-names></name><name><surname>Wu</surname><given-names>JH</given-names></name><name><surname>Singh</surname><given-names>T</given-names></name><name><surname>Liu</surname><given-names>JH</given-names></name><name><surname>Tsai</surname><given-names>MS</given-names></name><etal/></person-group><year>2006</year><article-title>Interactions of the fucose-specific Pseudomonas aeruginosa lectin, PA-IIL, with mammalian glycoconjugates bearing polyvalent Lewis(a) and ABH blood group glycotopes.</article-title><source>Biochimie</source><volume>88</volume><fpage>1479</fpage><lpage>1492</lpage><pub-id pub-id-type="pmid">16762477</pub-id></citation></ref><ref id="pone.0004270-Cohen1"><label>17</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cohen</surname><given-names>BH</given-names></name><name><surname>Bias</surname><given-names>WB</given-names></name><name><surname>Chase</surname><given-names>GA</given-names></name><name><surname>Diamond</surname><given-names>EL</given-names></name><name><surname>Graves</surname><given-names>CG</given-names></name><etal/></person-group><year>1980</year><article-title>Is ABH nonsecretor status a risk factor for obstructive lung disease?</article-title><source>Am J Epidemiol</source><volume>111</volume><fpage>285</fpage><lpage>291</lpage><pub-id pub-id-type="pmid">7361751</pub-id></citation></ref><ref id="pone.0004270-Kauffmann1"><label>18</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kauffmann</surname><given-names>F</given-names></name><name><surname>Frette</surname><given-names>C</given-names></name><name><surname>Pham</surname><given-names>QT</given-names></name><name><surname>Nafissi</surname><given-names>S</given-names></name><name><surname>Bertrand</surname><given-names>JP</given-names></name><etal/></person-group><year>1996</year><article-title>Associations of blood group-related antigens to FEV1, wheezing, and asthma.</article-title><source>Am J Respir Crit Care Med</source><volume>153</volume><fpage>76</fpage><lpage>82</lpage><pub-id pub-id-type="pmid">8542166</pub-id></citation></ref><ref id="pone.0004270-Ronchetti1"><label>19</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ronchetti</surname><given-names>F</given-names></name><name><surname>Villa</surname><given-names>MP</given-names></name><name><surname>Ronchetti</surname><given-names>R</given-names></name><name><surname>Bonci</surname><given-names>E</given-names></name><name><surname>Latini</surname><given-names>L</given-names></name><etal/></person-group><year>2001</year><article-title>ABO/Secretor genetic complex and susceptibility to asthma in childhood.</article-title><source>Eur Respir J</source><volume>17</volume><fpage>1236</fpage><lpage>1238</lpage><pub-id pub-id-type="pmid">11491170</pub-id></citation></ref><ref id="pone.0004270-Drumm1"><label>20</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Drumm</surname><given-names>ML</given-names></name><name><surname>Konstan</surname><given-names>MW</given-names></name><name><surname>Schluchter</surname><given-names>MD</given-names></name><name><surname>Handler</surname><given-names>A</given-names></name><name><surname>Pace</surname><given-names>R</given-names></name><etal/></person-group><year>2005</year><article-title>Genetic modifiers of lung disease in cystic fibrosis.</article-title><source>N Engl J Med</source><volume>353</volume><fpage>1443</fpage><lpage>1453</lpage><pub-id pub-id-type="pmid">16207846</pub-id></citation></ref><ref id="pone.0004270-Schluchter1"><label>21</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Schluchter</surname><given-names>MD</given-names></name><name><surname>Konstan</surname><given-names>MW</given-names></name><name><surname>Drumm</surname><given-names>ML</given-names></name><name><surname>Yankaskas</surname><given-names>JR</given-names></name><name><surname>Knowles</surname><given-names>MR</given-names></name></person-group><year>2006</year><article-title>Classifying severity of cystic fibrosis lung disease using longitudinal pulmonary function data.</article-title><source>Am J Respir Crit Care Med</source><volume>174</volume><fpage>780</fpage><lpage>786</lpage><pub-id pub-id-type="pmid">16858011</pub-id></citation></ref><ref id="pone.0004270-Svensson1"><label>22</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Svensson</surname><given-names>L</given-names></name><name><surname>Petersson</surname><given-names>A</given-names></name><name><surname>Henry</surname><given-names>SM</given-names></name></person-group><year>2000</year><article-title>Secretor genotyping for A385T, G428A, C571T, C628T, 685delTGG, G849A, and other mutations from a single PCR.</article-title><source>Transfusion</source><volume>40</volume><fpage>856</fpage><lpage>860</lpage><pub-id pub-id-type="pmid">10924615</pub-id></citation></ref><ref id="pone.0004270-Salomaa1"><label>23</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Salomaa</surname><given-names>V</given-names></name><name><surname>Pankow</surname><given-names>J</given-names></name><name><surname>Heiss</surname><given-names>G</given-names></name><name><surname>Cakir</surname><given-names>B</given-names></name><name><surname>Eckfeldt</surname><given-names>JH</given-names></name><etal/></person-group><year>2000</year><article-title>Genetic background of Lewis negative blood group phenotype and its association with atherosclerotic disease in the NHLBI family heart study.</article-title><source>J Intern Med</source><volume>247</volume><fpage>689</fpage><lpage>698</lpage><pub-id pub-id-type="pmid">10886491</pub-id></citation></ref><ref id="pone.0004270-Cameron1"><label>24</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cameron</surname><given-names>HS</given-names></name><name><surname>Szczepaniak</surname><given-names>D</given-names></name><name><surname>Weston</surname><given-names>BW</given-names></name></person-group><year>1995</year><article-title>Expression of human chromosome 19p alpha(1,3)-fucosyltransferase genes in normal tissues. Alternative splicing, polyadenylation, and isoforms.</article-title><source>J Biol Chem</source><volume>270</volume><fpage>20112</fpage><lpage>20122</lpage><pub-id pub-id-type="pmid">7650030</pub-id></citation></ref><ref id="pone.0004270-Pang1"><label>25</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Pang</surname><given-names>H</given-names></name><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Koda</surname><given-names>Y</given-names></name><name><surname>Soejima</surname><given-names>M</given-names></name><name><surname>Jia</surname><given-names>J</given-names></name><etal/></person-group><year>1998</year><article-title>Five novel missense mutations of the Lewis gene (FUT3) in African (Xhosa) and Caucasian populations in South Africa.</article-title><source>Hum Genet</source><volume>102</volume><fpage>675</fpage><lpage>680</lpage><pub-id pub-id-type="pmid">9703429</pub-id></citation></ref><ref id="pone.0004270-Harmening1"><label>26</label><citation citation-type="book"><person-group person-group-type="author"><name><surname>Harmening</surname><given-names>D</given-names></name></person-group><year>1999</year><article-title>Modern Blood Banking and Transfusion Practice;</article-title><person-group person-group-type="editor"><name><surname>Harmening</surname><given-names>D</given-names></name></person-group><publisher-loc>Philadelphia</publisher-loc><publisher-name>F.A. Davis Company</publisher-name></citation></ref><ref id="pone.0004270-dbSNP1"><label>27</label><citation citation-type="journal">dbSNP</citation></ref><ref id="pone.0004270-Orntoft1"><label>28</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Orntoft</surname><given-names>TF</given-names></name><name><surname>Vestergaard</surname><given-names>EM</given-names></name><name><surname>Holmes</surname><given-names>E</given-names></name><name><surname>Jakobsen</surname><given-names>JS</given-names></name><name><surname>Grunnet</surname><given-names>N</given-names></name><etal/></person-group><year>1996</year><article-title>Influence of Lewis alpha1-3/4-L-fucosyltransferase (FUT3) gene mutations on enzyme activity, erythrocyte phenotyping, and circulating tumor marker sialyl-Lewis a levels.</article-title><source>J Biol Chem</source><volume>271</volume><fpage>32260</fpage><lpage>32268</lpage><pub-id pub-id-type="pmid">8943285</pub-id></citation></ref><ref id="pone.0004270-Rhim1"><label>29</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rhim</surname><given-names>AD</given-names></name><name><surname>Stoykova</surname><given-names>L</given-names></name><name><surname>Glick</surname><given-names>MC</given-names></name><name><surname>Scanlin</surname><given-names>TF</given-names></name></person-group><year>2001</year><article-title>Terminal glycosylation in cystic fibrosis (CF): a review emphasizing the airway epithelial cell.</article-title><source>Glycoconj J</source><volume>18</volume><fpage>649</fpage><lpage>659</lpage><pub-id pub-id-type="pmid">12386452</pub-id></citation></ref><ref id="pone.0004270-PittmanJ1"><label>30</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Pittman J</surname><given-names>CH</given-names></name><name><surname>Yeatts</surname><given-names>J</given-names></name><name><surname>Drumm</surname><given-names>M</given-names></name><name><surname>Leigh</surname><given-names>M</given-names></name><name><surname>Davis</surname><given-names>S</given-names></name><name><surname>Van Rie</surname><given-names>A</given-names></name><name><surname>Emomnd</surname><given-names>M</given-names></name><name><surname>Knowles</surname><given-names>M</given-names></name></person-group><year>2008</year><article-title>Age of Pseudomonas Aeruginosa Infection and Severity of Adult Lung Disease in Cystic Fibrosis.</article-title><source>Pediatric Pulmonology</source><volume>43</volume><fpage>A332</fpage></citation></ref><ref id="pone.0004270-Rowntree1"><label>31</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rowntree</surname><given-names>RK</given-names></name><name><surname>Harris</surname><given-names>A</given-names></name></person-group><year>2003</year><article-title>The phenotypic consequences of CFTR mutations.</article-title><source>Ann Hum Genet</source><volume>67</volume><fpage>471</fpage><lpage>485</lpage><pub-id pub-id-type="pmid">12940920</pub-id></citation></ref><ref id="pone.0004270-Kerem1"><label>32</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kerem</surname><given-names>E</given-names></name><name><surname>Corey</surname><given-names>M</given-names></name><name><surname>Kerem</surname><given-names>BS</given-names></name><name><surname>Rommens</surname><given-names>J</given-names></name><name><surname>Markiewicz</surname><given-names>D</given-names></name><etal/></person-group><year>1990</year><article-title>The relation between genotype and phenotype in cystic fibrosis&#x02013;analysis of the most common mutation (delta F508).</article-title><source>N Engl J Med</source><volume>323</volume><fpage>1517</fpage><lpage>1522</lpage><pub-id pub-id-type="pmid">2233932</pub-id></citation></ref><ref id="pone.0004270-Vanscoy1"><label>33</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Vanscoy</surname><given-names>LL</given-names></name><name><surname>Blackman</surname><given-names>SM</given-names></name><name><surname>Collaco</surname><given-names>JM</given-names></name><name><surname>Bowers</surname><given-names>A</given-names></name><name><surname>Lai</surname><given-names>T</given-names></name><etal/></person-group><year>2007</year><article-title>Heritability of lung disease severity in cystic fibrosis.</article-title><source>Am J Respir Crit Care Med</source><volume>175</volume><fpage>1036</fpage><lpage>1043</lpage><pub-id pub-id-type="pmid">17332481</pub-id></citation></ref><ref id="pone.0004270-Khan1"><label>34</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Khan</surname><given-names>TZ</given-names></name><name><surname>Wagener</surname><given-names>JS</given-names></name><name><surname>Bost</surname><given-names>T</given-names></name><name><surname>Martinez</surname><given-names>J</given-names></name><name><surname>Accurso</surname><given-names>FJ</given-names></name><etal/></person-group><year>1995</year><article-title>Early pulmonary inflammation in infants with cystic fibrosis.</article-title><source>Am J Respir Crit Care Med</source><volume>151</volume><fpage>1075</fpage><lpage>1082</lpage><pub-id pub-id-type="pmid">7697234</pub-id></citation></ref><ref id="pone.0004270-Haponik1"><label>35</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Haponik</surname><given-names>EF</given-names></name><name><surname>Stokes</surname><given-names>D</given-names></name><name><surname>Rosenstein</surname><given-names>BJ</given-names></name><name><surname>Hughes</surname><given-names>WT</given-names></name></person-group><year>1985</year><article-title>ABH secretor status in cystic fibrosis&#x02013;a negative report.</article-title><source>Eur J Respir Dis</source><volume>67</volume><fpage>381</fpage><lpage>384</lpage><pub-id pub-id-type="pmid">4085589</pub-id></citation></ref><ref id="pone.0004270-Shori1"><label>36</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Shori</surname><given-names>DK</given-names></name><name><surname>Genter</surname><given-names>T</given-names></name><name><surname>Hansen</surname><given-names>J</given-names></name><name><surname>Koch</surname><given-names>C</given-names></name><name><surname>Wyatt</surname><given-names>H</given-names></name><etal/></person-group><year>2001</year><article-title>Altered sialyl- and fucosyl-linkage on mucins in cystic fibrosis patients promotes formation of the sialyl-Lewis X determinant on salivary MUC-5B and MUC-7.</article-title><source>Pflugers Arch</source><volume>443</volume><issue>Suppl 1</issue><fpage>S55</fpage><lpage>61</lpage><pub-id pub-id-type="pmid">11845304</pub-id></citation></ref><ref id="pone.0004270-Zemel1"><label>37</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zemel</surname><given-names>BS</given-names></name><name><surname>Jawad</surname><given-names>AF</given-names></name><name><surname>FitzSimmons</surname><given-names>S</given-names></name><name><surname>Stallings</surname><given-names>VA</given-names></name></person-group><year>2000</year><article-title>Longitudinal relationship among growth, nutritional status, and pulmonary function in children with cystic fibrosis: analysis of the Cystic Fibrosis Foundation National CF Patient Registry.</article-title><source>J Pediatr</source><volume>137</volume><fpage>374</fpage><lpage>380</lpage><pub-id pub-id-type="pmid">10969263</pub-id></citation></ref><ref id="pone.0004270-Imundo1"><label>38</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Imundo</surname><given-names>L</given-names></name><name><surname>Barasch</surname><given-names>J</given-names></name><name><surname>Prince</surname><given-names>A</given-names></name><name><surname>Al-Awqati</surname><given-names>Q</given-names></name></person-group><year>1995</year><article-title>Cystic fibrosis epithelial cells have a receptor for pathogenic bacteria on their apical surface.</article-title><source>Proc Natl Acad Sci U S A</source><volume>92</volume><fpage>3019</fpage><lpage>3023</lpage><pub-id pub-id-type="pmid">7708767</pub-id></citation></ref><ref id="pone.0004270-Devaraj1"><label>39</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Devaraj</surname><given-names>N</given-names></name><name><surname>Sheykhnazari</surname><given-names>M</given-names></name><name><surname>Warren</surname><given-names>WS</given-names></name><name><surname>Bhavanandan</surname><given-names>VP</given-names></name></person-group><year>1994</year><article-title>Differential binding of Pseudomonas aeruginosa to normal and cystic fibrosis tracheobronchial mucins.</article-title><source>Glycobiology</source><volume>4</volume><fpage>307</fpage><lpage>316</lpage><pub-id pub-id-type="pmid">7949656</pub-id></citation></ref><ref id="pone.0004270-Carnoy1"><label>40</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Carnoy</surname><given-names>C</given-names></name><name><surname>Ramphal</surname><given-names>R</given-names></name><name><surname>Scharfman</surname><given-names>A</given-names></name><name><surname>Lo-Guidice</surname><given-names>JM</given-names></name><name><surname>Houdret</surname><given-names>N</given-names></name><etal/></person-group><year>1993</year><article-title>Altered carbohydrate composition of salivary mucins from patients with cystic fibrosis and the adhesion of Pseudomonas aeruginosa.</article-title><source>Am J Respir Cell Mol Biol</source><volume>9</volume><fpage>323</fpage><lpage>334</lpage><pub-id pub-id-type="pmid">8398170</pub-id></citation></ref><ref id="pone.0004270-Komiyama1"><label>41</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Komiyama</surname><given-names>K</given-names></name><name><surname>Habbick</surname><given-names>BF</given-names></name><name><surname>Tumber</surname><given-names>SK</given-names></name></person-group><year>1987</year><article-title>Role of sialic acid in saliva-mediated aggregation of Pseudomonas aeruginosa isolated from cystic fibrosis patients.</article-title><source>Infect Immun</source><volume>55</volume><fpage>2364</fpage><lpage>2369</lpage><pub-id pub-id-type="pmid">3115896</pub-id></citation></ref><ref id="pone.0004270-Clamp1"><label>42</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Clamp</surname><given-names>JR</given-names></name><name><surname>Gough</surname><given-names>M</given-names></name></person-group><year>1979</year><article-title>Study of the oligosaccharide units from mucus glycoproteins of meconium from normal infants and from cases of cystic fibrosis with meconium ileus.</article-title><source>Clin Sci (Lond)</source><volume>57</volume><fpage>445</fpage><lpage>451</lpage><pub-id pub-id-type="pmid">519953</pub-id></citation></ref><ref id="pone.0004270-Thiru1"><label>43</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Thiru</surname><given-names>S</given-names></name><name><surname>Devereux</surname><given-names>G</given-names></name><name><surname>King</surname><given-names>A</given-names></name></person-group><year>1990</year><article-title>Abnormal fucosylation of ileal mucus in cystic fibrosis: I. A histochemical study using peroxidase labelled lectins.</article-title><source>J Clin Pathol</source><volume>43</volume><fpage>1014</fpage><lpage>1018</lpage><pub-id pub-id-type="pmid">2266173</pub-id></citation></ref><ref id="pone.0004270-Thomsson1"><label>44</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Thomsson</surname><given-names>KA</given-names></name><name><surname>Hinojosa-Kurtzberg</surname><given-names>M</given-names></name><name><surname>Axelsson</surname><given-names>KA</given-names></name><name><surname>Domino</surname><given-names>SE</given-names></name><name><surname>Lowe</surname><given-names>JB</given-names></name><etal/></person-group><year>2002</year><article-title>Intestinal mucins from cystic fibrosis mice show increased fucosylation due to an induced Fucalpha1-2 glycosyltransferase.</article-title><source>Biochem J</source><volume>367</volume><fpage>609</fpage><lpage>616</lpage><pub-id pub-id-type="pmid">12164788</pub-id></citation></ref><ref id="pone.0004270-Elmgren1"><label>45</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Elmgren</surname><given-names>A</given-names></name><name><surname>Grahn</surname><given-names>A</given-names></name><name><surname>Gronowitz</surname><given-names>E</given-names></name><name><surname>Aberg</surname><given-names>L</given-names></name><name><surname>Heikenheimo</surname><given-names>M</given-names></name><etal/></person-group><year>2002</year><article-title>Lewis and secretor genotypes modify the phenotype in patients with cystic fibrosis.</article-title><source>Pediatric Pulmonology</source><volume>34</volume><fpage>226</fpage><pub-id pub-id-type="pmid">12203853</pub-id></citation></ref><ref id="pone.0004270-Bremer1"><label>46</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bremer</surname><given-names>LA</given-names></name><name><surname>Blackman</surname><given-names>SM</given-names></name><name><surname>Vanscoy</surname><given-names>LL</given-names></name><name><surname>McDougal</surname><given-names>KE</given-names></name><name><surname>Bowers</surname><given-names>A</given-names></name><etal/></person-group><year>2008</year><article-title>Interaction between a novel TGFB1 haplotype and CFTR genotype is associated with improved lung function in cystic fibrosis.</article-title><source>Hum Mol Genet</source><volume>17</volume><fpage>2228</fpage><lpage>2237</lpage><pub-id pub-id-type="pmid">18424453</pub-id></citation></ref></ref-list><fn-group><fn fn-type="conflict"><p><bold>Competing Interests: </bold>The authors have declared that no competing interests exist.</p></fn><fn fn-type="financial-disclosure"><p><bold>Funding: </bold>This work was supported by NIH HL068890, NIH 1F32HL082207-01, and the GlaxoSmithKline Pulmonary Fellowship Award. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.</p></fn></fn-group></back></article> 